12:00 AM
Jul 23, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Adcetris brentuximab vedotin regulatory update

EMA's CHMP recommended conditional approval of an MAA from Takeda for Adcetris brentuximab vedotin for relapsed or refractory CD30-positive Hodgkin's lymphoma following autologous stem cell transplant (ASCT) or following at least 2 prior therapies when ASCT or multi-agent chemotherapy is not a treatment...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >